Flexible, innovative solutions for analysis of the skeleton


The following list links out to recent peer reviewed publications containing work performed by the skelet.AL team


Three-dimensional local measurements of bone strain and displacement: comparison of three digital volume correlation approaches. (J Biomech Eng. 2015)

The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. (Nature. 2015)

Lack of prolidase causes a bone phenotype both in human and in mouse. (Bone. 2015)


About the inevitable compromise between spatial resolution and accuracy of strain measurement for bone tissue: a 3D zero-strain study. (J Biomech. 2014)

Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. (J Bone Miner Res. 2014)


The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading. (J Bone Miner Res. 2013)

Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5. (PLoS One. 2013)


A Soluble bone morphogenetic protein type 1A receptor increases bone mass and bone strength (PNAS 2012)

Bone healing response to a synthetic calcium sulfate/β-tricalcium phosphate graft material in a sheep vertebral body defect model. (Journal of Biomedical Materials Research 2012)

Prdm5 regulates collagen gene transcription by association with RNA polymerase II in developing bone. (PLoS Genet 2012)

Inhibitor Rcan2 Have an Isolated Defect of Osteoblast Function. (Endocrinology 2012)

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. (Leukemia 2012)

Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. (PLoS Genet 2012)

A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a Col2a1 mutation. (J Bone Miner Res 2012)

2009 – 11

LOXL2-mediated matrix remodelling in metastasis and mammary gland involution (Cancer Res 2011).

Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts (PNAS 2010)

Inhibiting activin-A signalling stimulates bone formation and prevents cancer induced bone destruction in vivo. (J Bone Miner Res 2010)

Cancer-induced bone loss and associated pain-related behaviour is reduced by risedronate but not its phosphocarboxylate analog NE-10790. (Int J Cancer 2009)

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. (J Bone Miner Res 2009)

2007 – 08

Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. (Biochem Biophys Res Commun 2008)

An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma. (Cancer Res 2007)

A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. (Leukemia 2007)

Targeting the IGF-1R using picropodophyllin (PPP) in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. (Int J Cancer 2007)

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone. (Cancer Res 2007)

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. (Cancer Res 2009)

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. (Clin Exp Metastasis 2006)

Mutations in VAPB are not associated with sporadic ALS. (Neurology 2007)